{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:45:35Z","timestamp":1777023935758,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007623","name":"Emory University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.mcna.2025.12.006","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:18:35Z","timestamp":1777018715000},"page":"377-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Noninsulin Medications for Type 2 Diabetes"],"prefix":"10.1016","volume":"110","author":[{"given":"Iris","family":"Castro-Revoredo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C. Markley","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mcna.2025.12.006_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.mcna.2025.12.006_bib2","first-page":"1747","article-title":"Oral agents in the management of type 2 diabetes mellitus","volume":"63","author":"Luna","year":"2001","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.mcna.2025.12.006_bib3","series-title":"Mortality in the United States, 2023. NCHS Data Brief, no. 521","author":"Murphy","year":"2024"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib4","first-page":"389","article-title":"Novel therapies with precision mechanisms for type 2 diabetes mellitus","volume":"17","author":"Perreault","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.mcna.2025.12.006_bib5","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 2025."},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib7","first-page":"44","article-title":"Pharmacotherapies for diabetes management: an update for the practicing clinician","volume":"18","author":"Meneghini","year":"2006","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib8","article-title":"Approach to the patient with type 2 diabetes requiring add-on medication","volume":"109","author":"Baum","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2025.12.006_bib10","first-page":"S266","article-title":"13. Older adults: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/diaspect.27.2.82","article-title":"A brief history of the development of diabetes medications","volume":"27","author":"White","year":"2014","journal-title":"Diabetes Spectr"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2025.12.006_bib12","first-page":"S1","article-title":"Standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.mcna.2025.12.006_bib13","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2174\/0109298673289342240213040144","article-title":"Metformin effects on SHIP2, AMPKs and gut microbiota: recent updates on pharmacology","volume":"32","author":"Shivaprakash","year":"2025","journal-title":"Curr Med Chem"},{"issue":"9131","key":"10.1016\/j.mcna.2025.12.006_bib14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2025.12.006_bib15","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2337\/dc14-1395","article-title":"Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a Diabetes Care Editors\u2019 Expert Forum","volume":"37","author":"Cefalu","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mcna.2025.12.006_bib16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.mcna.2025.12.006_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ecl.2013.06.005","article-title":"Complications of diabetes therapy","volume":"42","author":"Corathers","year":"2013","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23067","article-title":"Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors","volume":"8","author":"Turchin","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.mcna.2025.12.006_bib19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","article-title":"Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline","volume":"107","author":"Korytkowski","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005165","article-title":"Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes","volume":"4","author":"Rajendran","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.mcna.2025.12.006_bib21","first-page":"2055","article-title":"A dose-response study of repaglinide in patients with type 2 diabetes","volume":"21","author":"Goldberg","year":"1998","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.mcna.2025.12.006_bib22","first-page":"1625","article-title":"Meglitinide analogues in the treatment of type 2 diabetes mellitus: a focus on repaglinide","volume":"61","author":"Landgraf","year":"2001","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.mcna.2025.12.006_bib23","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.mcna.2025.12.006_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"issue":"9493","key":"10.1016\/j.mcna.2025.12.006_bib25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.mcna.2025.12.006_bib26","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.12.006_bib27","unstructured":"Endocrine Society,2022."},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib28","article-title":"Alpha-glucosidase inhibitors for type 2 diabetes mellitus","author":"Van de Laar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.mcna.2025.12.006_bib29","first-page":"1921","article-title":"SOUL trial investigators. Cardiovascular outcomes with oral semaglutide in type 2 diabetes","volume":"391","author":"Zinman","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2025.12.006_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2025.12.006_bib32","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2025.12.006_bib34","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-25-01791-JC","article-title":"In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs placebo at a median 14 mo","volume":"178","author":"Thakkar","year":"2025","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metabol"},{"issue":"10401","key":"10.1016\/j.mcna.2025.12.006_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.mcna.2025.12.006_bib39","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.mcna.2025.12.006_bib40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2025.12.006_bib41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/dc17-2212","article-title":"The risk of acute pancreatitis after initiation of dipeptidyl peptidase 4 inhibitors: testing a hypothesis of subgroup differences in older U.S. adults","volume":"41","author":"Hong","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4158\/EP-2019-0481","article-title":"Safety and efficacy of DPP-4 inhibitors for the management of hospitalized general medicine and surgery patients with type 2 diabetes","volume":"26","author":"Lorenzo-Gonz\u00e1lez","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.mcna.2025.12.006_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2025.12.006_bib44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mcna.2025.12.006_bib45","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2025.12.006_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.mcna.2025.12.006_bib47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2025.12.006_bib48","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"LEADER Publication Committee on behalf of the LEADER trial investigators. Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman","year":"2018","journal-title":"Diabetes Ther"},{"issue":"19","key":"10.1016\/j.mcna.2025.12.006_bib49","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"FLOW trial committees and investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib51","first-page":"377","article-title":"Glucagon-like peptide-1 receptor agonists in hospitalized patients with diabetes: a review of the evidence and practical considerations","volume":"45","author":"Jervis","year":"2022","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.mcna.2025.12.006_bib52","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"issue":"10403","key":"10.1016\/j.mcna.2025.12.006_bib53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2025.12.006_bib54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2025.12.006_bib55","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcna.2025.12.006_bib56","first-page":"153","article-title":"Retatrutide phase 2 obesity trial investigators. Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2025.12.006_bib57","first-page":"465","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.mcna.2025.12.006_bib58","first-page":"221","article-title":"Enhanced glycemic control with combination therapy for type 2 diabetes in primary care","volume":"2","author":"Kuritzky","year":"2011","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.mcna.2025.12.006_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211042145","article-title":"Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice","volume":"12","author":"Shah","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.mcna.2025.12.006_bib60","first-page":"S1","article-title":"American Diabetes Association. Standards of Care in Diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.mcna.2025.12.006_bib61","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc24-SREV","article-title":"Summary of Revisions: Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2025.12.006_bib62","unstructured":"Lexicomp Online, Lexi-Drugs. Wolters Kluwer Health, Inc. https:\/\/online.lexi.com. Accessed June 2024."},{"key":"10.1016\/j.mcna.2025.12.006_bib63","unstructured":"US FDA Drug Database. https:\/\/open.fda.gov\/data\/drugfda\/. Accessed June 2024."},{"key":"10.1016\/j.mcna.2025.12.006_bib64","unstructured":"GoodRX. Average retail prices for diabetes medications. https:\/\/www.goodrx.com. Accessed June 2024."},{"issue":"24","key":"10.1016\/j.mcna.2025.12.006_bib65","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes with Tirzepitide Vs Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2025.12.006_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309618","article-title":"Prevalence and predictors of hypoglycemia in older outpatients with type 2 diabetes mellitus","volume":"19","author":"Al-Azayzih","year":"2024","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.mcna.2025.12.006_bib67","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamainternmed.2014.1824","article-title":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among medicare beneficiaries, 1999 to 2011","volume":"174","author":"Lipska","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.12.006_bib68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamainternmed.2014.7345","article-title":"Potential overtreatment of diabetes mellitus in older adults with tight glycemic control","volume":"175","author":"Lipska","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mcna.2025.12.006_bib69","doi-asserted-by":"crossref","unstructured":"Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. Published online December 17, 2025 https:\/\/doi.org\/10.1038\/s41586-025-10026-ws.","DOI":"10.1038\/s41586-025-10026-w"},{"issue":"3","key":"10.1016\/j.mcna.2025.12.006_bib70","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:52:27Z","timestamp":1777020747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0025712525001944"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.12.006","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninsulin Medications for Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}